Physician profile
Marlanea Jarrell
NPI 1013501857
$2,665.99
in general payments reported to CMS, 2019-2025
20 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $649 · 2022: $966 · 2023: $384 · 2024: $156 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024 · Education: $26.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.47 |
| Education | $26.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $560.11 | 2021-2023 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $385.56 | 2021-2023 | |
| Aurinia Pharma U.S., INC. | $183.86 | 2021-2023 | Lupkynis |
| Vanda Pharmaceuticals INC. | $183.09 | 2025 | Fanapt |
| Vifor Pharma, INC. | $167.71 | 2022-2023 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $163.76 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $136.41 | 2025 | Caplyta |
| Travere Therapeutics, INC. | $133.21 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $131.66 | 2023-2024 | Uzedy |
| Amgen INC. | $128.99 | 2021-2023 | Tavneos, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $125.60 | 2023-2025 | Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $91.10 | 2022 | |
| Novo Nordisk INC | $63.02 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $48.92 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $43.96 | 2025 | Cobenfy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $39.68 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.38 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.78 | 2021 | |
| Calliditas Therapeutics US INC. | $18.69 | 2022 | |
| Glaxosmithkline, LLC. | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlanea Jarrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.